Meal context and food preferences in cancer patients: results from a French self-report survey by unknown
Guerdoux‑Ninot et al. SpringerPlus  (2016) 5:810 
DOI 10.1186/s40064‑016‑2538‑1
RESEARCH
Meal context and food preferences 
in cancer patients: results from a French 
self‑report survey
Estelle Guerdoux‑Ninot1,2*, Robert D. Kilgour3,4, Chloé Janiszewski5,6, Marta Jarlier7, Jocelyne Meuric8,11, 
Brigitte Poirée9,11, Solange Buzzo10,11, Grégory Ninot1,2, Julie Courraud1, Wendy Wismer12, Simon Thezenas7 
and Pierre Senesse1,2,5,11
Abstract 
Purpose: The present study examined patient self‑reports of descriptions, experiences and consequences of meal 
disturbances and food preferences within a cultural context (i.e., French meal traditions) in various treated cancer 
patients along their disease trajectory.
Methods: Over 800 questionnaires were sent to 20 cancer treatment centres in France. During a 9‑month period, 255 
questionnaires were received from five centres. Inclusion criteria included those French patients over 18 years of age, 
could read and understand French, had an Eastern Cooperative Oncology Group score between 0 and 2, experienced 
treatment‑induced nutrition changes and/or had decreased oral intake. Dietetic staff assessed clinical characteristics 
while patients completed a 17‑item questionnaire.
Results: The majority of patients were diagnosed with breast, gastro‑intestinal (GI) tract and head and neck can‑
cers (62 %). Half of the patients (49 %) experienced weight loss >5 %. The main treatment‑induced side effects were 
fatigue, nausea, dry mouth, hypersensitivity to odors and GI tract transit disorders. These discomforts affected eating 
and drinking in 83 % of patients, inducing appetite loss and selected food aversion. Food preference appeared hetero‑
geneous. Food taste, odor and finally appearance stimulated appetite. Finally, dietary behaviors and satisfaction were 
driven by the extent to which food was enjoyed.
Conclusions: During oncologic treatments, eating and drinking were affected in more than three‑quarters of 
patients. As recommended by practice guidelines, nutritional assessment and follow‑up are required. Personalized 
nutritional counseling should include the role of the family, patient’s meal traditions, and food habits.
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Background
In disease-free adults, daily food intake is distributed 
over many meals and snacks. The traditional meal defini-
tion in the European culture is a social event that occurs 
on a regular daily basis at relatively fixed hours, includ-
ing several dishes presented in succession (Bellisle et al. 
2003). Traditionally, French adults are used to ingest-
ing three meals a day. The interval that separates lunch 
from dinner in the French culture is traditionally inter-
rupted by a small snack that produces long lasting sati-
ety and that accounts for, on average, 18.5 % of the total 
daily energy intake (Bellisle et  al. 2003). However, sev-
eral factors affect meals in the natural environment, such 
as social facilitation, subjective hunger, food hedonics, 
learned habits, and palatability. Food hedonics is one 
component of the eating and drinking experience and 
refers to a psychological determination of the extent to 
which eating and drinking provides feeling of pleasure or 
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displeasure (Boltong et  al. 2012). Palatability is defined 
as the stimulus quality of a substance which determines 
its acceptability (de Castro et al. 2000). In a study includ-
ing French participants, higher levels of palatability 
were found to be related to larger meal portions, meal 
duration, smaller satiety ratios, greater hunger, and less 
anxiety/depression (de Castro et  al. 2000). Inciden-
tally, palatability has large effects on intake regardless 
of culture (i.e., for the North American and the French 
cultures) but appears to be only one of many factors 
influencing intake (de Castro 2000).
Moreover, several studies have demonstrated an altered 
food preference in cancer, and food-related quality of life 
depending on treatment or disease stage (Epstein et  al. 
2002; Hovan et al. 2010). Patients with head and neck can-
cers had altered food-related expectations and changes in 
the “meaning of food” resulting in physical, emotional and 
social losses (McQuestion et  al. 2011). Following cura-
tive gastrectomy, patients experienced increased dyspha-
gia, eating restriction, anxiety, taste changes, and body 
image scores which gradually decreased over 12 months 
(Kong et  al. 2012). Radiotherapy is also well known to 
impair taste perception during and after cancer treatment 
(e.g., Ruo Redda and Allis 2006; Irune et al. 2014). Taste 
changes and food preferences are also expressed differ-
ently according to chemotherapy (CT) regimen with sig-
nificant relationships between ageusia and dry mouth, 
bitter taste and appetite loss, sour taste and nausea, and 
anorexia and dry mouth (Zabernigg et al. 2010). As high-
lighted by recent systematic reviews, the influence of CT 
changes in food preferences have not been consistently 
demonstrated (Epstein and Barasch 2010; Boltong and 
Keast 2012; Gamper et  al. 2012). Finally, the extent to 
which these disturbances play a role in dietary behavior 
during and after treatment remains relatively unknown. 
Despite randomized trials of dietary counseling compared 
to no dietary counseling or to standard practice (e.g., Isen-
ring et al. 2007), there is a lack of information concerning 
practical management of food intake, particularly meal 
and food preferences in a cultural context among cancer 
patients undergoing treatment.
The approach of this study was to explore meal and 
food preferences among cancer patients within a cul-
tural context (i.e., including meal traditions) because of 
its pregnant role in feeding behaviors. Therefore, we con-
ducted a multi-centre study to investigate self-reported 
descriptions and experiences of the meals context and 
food preferences in cancer patients.
Methods
Study population and design
Over a 9-month period, patient self-report surveys were 
completed anonymously and used to explore patient 
descriptions, experiences and consequences of meal 
disturbances.
Height hundred questionnaires were sent from the 
lead investigation site (Cancer Institute of Montpellier, 
ICM) to 20 cancer treatment centres in France. Ethical 
approval to conduct this study and to publish the results 
was granted from the government through the “Oséo 
program” Grant. Patients were eligible for inclusion if: 
(1) they were aged 18 years or over; (2) they were French 
by culture, were able to read and understand French; 
(3) they had an Eastern Cooperative Oncology Group 
(ECOG) Performance Status score of 0, 1 or 2; (4) they 
had self-reported oral intake changes related to treatment 
during the dietician clinical assessments; and/or 5) they 
had an ingesta visual analogue scale (ingesta-VAS) score 
<8 (Thibault et al. 2011; Senesse et al. 2014). The ingesta-
VAS was used for a quick assessment of dietary intake 
in clinical practice, particularly in patients with weight 
loss (0  =  no ingesta; 10  =  usual ingesta). This scale is 
highly correlated with caloric intake (p < 0.0001). Patients 
defined themselves their level of ingestion of food by 
ticking a 100-mm line traced on a paper to answer the 
inquiry “How much do you currently eat on a scale from 
0 “nothing at all” (far left side of the line) to 10 “as usual” 
(far right side of the line)?” (Thibault et al. 2011).
Material and procedure
In line with Boltong et al. (2012), the questionnaire was 
developed by a working group of students, dietitians, 
medical residents, physicians, and food industry profes-
sionals with product development experience. A pilot 
test of the questionnaire was conducted with 20 patients 
to ensure item clarity. No change was made to the ques-
tionnaire following this test phase.
Dietitians assessed patient demographic and clinical 
characteristics (e.g., tumor location, anticancer treatment, 
weight loss), and provided instruction for completion of 
the questionnaire. The questionnaire consisted of 17 items 
(Table  1) that related to the description of (1) treatment-
related side effects and their impact on eating and drinking; 
(2) cooking skills; (3) dietary behavior; (4) food preference; 
(5); experiences with nutrient-enriched food; and (6) pref-
erences for a new dietary product. The questionnaire con-
tained open-ended and multiple-choice questions with an 
opportunity to provide alternative answers and to choose 
more than one answer. Two additional questions were 
about food attributes that stimulate appetite (#4.4) and the 
advantages that motivate the purchase of new dietary prod-
ucts (#6.1). For these two items, the answers were ranked in 
descending order of importance on a 7-point and a 9-point 
scale, respectively (1 = most important).
Patients’ written informed consent was obtained prior 
to the completion of the questionnaire. Institutional 
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review boards of each investigational site approved the 
study protocol. Questionnaires were returned to the ICM 
for data analysis.
Statistical considerations
Categorical variables were reported by means of fre-
quency and percentages. For continuous variables, medi-
ans, means, standard deviations and range values were 
computed. The association between demographic, clini-
cal characteristics and different items included in the 
self-report questionnaire was assessed using Pearson’s 
Chi square test or Fisher’s exact test when applicable for 
categorical variables, and using Kruskal–Wallis or Stu-
dent T test for continuous variables.
All reported p-values are two-sided and were consid-
ered significant at the 5  % level. Data from open-ended 
questions were handled and analysed with NVivo10 
software, which usually supports qualitative methods 
research. In the current study, they were explored using 
descriptive content analysis. Themes are only reported 
with quotes considered to be typical unless explicitly 
noted (Sandelowski 2010). Only brief comments from the 
qualitative analysis are reported. Statistical analysis was 
performed using STATA v.11.0 software (Stata Corpora-
tion, College Station, TX, USA).
Results
Patient sample
From the 800 distributed questionnaires, 255 were returned 
(31.8 %) from the 20 oncology-specialized hospitals, in par-
ticular from the ICM, the Francois Baclesse Center of Caen, 
the Curie Institute of Paris, the Paoli Calmettes Institute 
Table 1 Self-report questionnairea
a Translated from French to English
#1 Cancer treatment side effects and their impact on eating and drinking
 #1.1 Describe the side effects induced by the treatment: nausea, swallowing difficulties, mouth ulcers, constipation, dry mouth, chewing difficulties, 
persistent taste, diarrhea, fatigue, hypersensitivity to odors, vomiting, and/or others.
 #1.2 Do these side effects disturb your eating and drinking? Yes or no.
If yes, describe how: appetite loss, mouth and esophagus pain, fast fullness, food aversion, digestion pain, and/or other.
 #1.3 How long do these difficulties persist after treatment?
#2 Cooking skills
 #2.1 Are you able to cook as soon as you come back home? Yes, no or only after n days.
 #2.2 Are you helped by: a parent/family member/relative, home delivery, ready‑to‑eat products, and/or others?
#3 Dietary behavior
 #3.1 What meals and/or snacks do you currently have in one day? Breakfast, light morning meal, lunch, light mid‑afternoon meal, dinner, and/or 
other.
 #3.2 What is currently your favorite meal? Breakfast, light morning meal, lunch, light mid‑afternoon meal, dinner, and/or no preference.
 #3.3 What portion would you eat if a full meal was served to you in the hospital or at home? For the first course, for the second course, for the cheese 
and/or yogurt, for the dessert, and/or for the snack, would you eat 0, 1/4, 1/2, 3/4, 1 or 2 portions?
#4 Food preferences
 #4.1 What do you currently prefer to eat: salty, sweet, hot, cold, into pieces, minced, blended, creamy, liquid, and/or other?
 #4.2 Since the beginning of the treatment, what food, salty or sweet courses do you prefer to eat?
 #4.3 Specify for what foods you have developed nausea or an aversion.
 #4.4 What are the most important food attributes that stimulate your appetite (in descending order of importance from 1 to 7): taste, aspect, odor, 
consistency, quantity, presentation, and/or other?
 #4.5 What type of snacks do you prefer to eat: salty, sweet, creamy desserts, ice creams, biscuits, milky beverages, others beverages, and/or others?
#5 Nutrient‑enriched foods
 #5.1 Have you already experimented with enriched or fortified foods? Yes or no.
If yes, in what context have you experimented with it: in the hospital, at home, and/or, other?
If yes, please specify: blended courses, creamy desserts, milky beverages, non‑milky beverages, and/or others?
If yes, are you satisfied with the products: very satisfied, satisfied or not satisfied? Please specify why.
#6 Preferences for a new dietary product
 #6.1 If new dietary products were developed, what advantages would motivate you to purchase them (in descending order of importance from 1 to 
9): taste, sale price, ready‑to‑eat, dietary counseling, medical prescription, mode of preservation, nutritional value, partial reimbursement, or 
others?
 #6.2 Where do you prefer to find these new products: pharmacies, dietary shops, supermarkets, and/or home delivery?
 #6.3 What type of new products would you prefer: frozen, canned, fresh or other?
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of Marseille, and the Antoine Lacassagne Center of Nice. 
Patients completed the questionnaires as outpatients 
(52.1  %), or inpatients (full-time hospitalization, 47.8  %). 
Patient characteristics are shown in Table 2. Patients were 
on average 59.5 years old (±13 years, SD), ranging from 22 
to 89 years. All of them were French by culture and adopted 
French meal traditions. Most were women (60.0 %), aged 
from 50 to 69 years (56.4 %), lived as a couple (69.8 %), had 
one or two children (64.4  %) and did not work (48.2  %) 
or were on sick leave (30.2  %). Tumors were localized 
mostly in breast (27.1 %), GI tract (22.0 %) and head and 
neck (12.9  %). Most patients received a single round of 
CT (71.4 %). Most patients had altered functional abilities; 
39.2 % of patients were restricted in their ability to conduct 
physically strenuous activities but were ambulatory and 
able to carry out work of a light or sedentary nature (ECOG 
performance status score of 1), and 28.2 % were ambulatory 
and capable of all self-care but unable to carry out any work 
activities (ECOG score of 2). Half of patients (50.4 %) suf-
fered from weight loss ≥5 % compared with their pre-treat-
ment weight (Fearon et al. 2011). Insufficient caloric intake, 
as defined by a score <8 at the ingesta visual analogue scale, 
was reported in 54.1 % of cases. Dietitians noticed that two-
thirds of patients suffering from weight loss ≥5 % (65.7 %) 
consumed sip feeds, 48.0 % split meals and 15.8 % had arti-
ficial nutrition. Side effects of cancer treatment impacting 
oral intake are detailed in Table 3.
Responses to the themes of the self‑report questionnaire
#1 Treatment‑related side effects and impact on eating 
and drinking
The main side effects induced by the treatment thera-
pies were fatigue (74.5  %), nausea (55.3  %), dry mouth 
(48.6 %), hypersensitivity to odors (35.7 %) and constipa-
tion (34.1  %). Most patients (54.5  %) reported digestive 
tract disorders such as constipation or diarrhea (Table 3). 
Treatment-related side effects affected eating and drink-
ing in 83.1  % of patients, principally inducing appetite 
loss (66.8 % of patients who reported an impact on eating 
and drinking), food aversion (51.4 %) and satiety (39.7 %) 
(Table 4). These disturbances on eating and drinking per-
sisted for 10.8  days on average after treatment (ranging 
from 1 to 120  days). From open questions in the ques-
tionnaires, we also identified patient-related theme of 
feeling disturbed by the side effects. The strongest mes-
sage from patients was that they experienced taste modi-
fications such as “I have no taste anymore” (centers of 
Marseille and Caen), “I have lost taste” (center of Mont-
pellier), “my taste has been modified” (center of Nice), “I 
have strange taste in my mouth” (center of Paris). They 
also qualitatively reported a loss of pleasure described as 
Table 2 Patient demographic and  clinical characteristics 
(n = 255)
a The Eastern Cooperative Oncology Group (ECOG) performance status refers to 
functional ability scores (ranged from 0 to 5) to quantify cancer patients general 
well‑being and activities of daily life
b The ingesta visual/verbal analogue scale is used for a quick assessment of 
dietary intake in clinical practice, particularly in patients with weight loss (0 = no 
ingesta; 10 = usual ingesta). This scale is highly correlated with caloric intake. 
Patients defined themselves their level of ingestion of food between 0 (nothing) 
and 10 (as usual)
c Patients were considered to be active if they had a job
d Patients were considered to be inactive if they had no job or were retired
Characteristic n (%)
Age
 <60 years 111 (43.5)
 ≥60 years 144 (56.5)
Female sex 153 (60.0)
ECOG performance statusa
 0 76 (29.8)
 1 100 (39.2)
 2 72 (28.2)
Side effects on oral intake 244 (95.7)
Ingesta visual analogue scaleb
 (0–6) 90 (35.3)
 (7 and 8) 48 (18.8)
 (8–10) 100 (39.2)
Artificial nutrition 38 (15.8)
Personal and professional status
 Live in southern France 143 (56.1)
 As a couple 178 (69.8)
 Activec 27 (10.6)
 Inactived 123 (48.2)
 Sick leave 77 (30.2)
Tumor location
 Breast 69 (27.1)
 Digestive system 56 (22.0)
 Head and neck 33 (12.9)
 Hematopoietic system 18 (7.1)
 Lung 17 (6.7)
 Gynecology 17 (6.7)
 Others 35 (13.7)
Anticancer treatment
 Chemotherapy 182 (71.4)
 Radiotherapy 7 (2.7)
 Chemotherapy + radiotherapy 26 (10.2)
 Surgery 23 (9.0)
 Others (e.g., antibiotic therapy) 11 (4.3)
Weight loss (compared with baseline) (%)
 <5 121 (47.5)
 5–10 59 (23.1)
 10–20 53 (20.8)
 ≥20 13 (5.1)
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“everything considerate, I feel a discomfort” or explicitly 
as “I have lost pleasure when eating and drinking”.
#2 Cooking skills
Over half the patients (53.3 %) were able to cook as soon 
as they returned home from a hospital day or from a 
treatment session (i.e., after a hospital stay), and 25.9 % 
started cooking again after 4–5  days. Patients’ parents 
were the main source of help (84.7 %) irrespective of the 
patients’ familial situation (i.e., as a couple or not).
#3 Dietary behavior
Patients reported to have daily dinner (91.8  %), break-
fast (90.2 %) and lunch (88.2 %). Outpatients (47.9 % of 
patients) had more lunch meals than inpatients (91.8 vs. 
83.0 %, p = 0.042) and tended to have more dinners (95.1 
vs. 88.4 %, p = 0.061). However, breakfast was identified 
as the favorite meal for 55.7 % of patients when compared 
with lunch and dinner (29.8 % and 20.4 %, respectively), 
whether they were an inpatient or outpatient.
A typical French meal consists of 4 courses: typically 
the “first course” (e.g., salad) is followed by the “second 
course” (e.g., meat with vegetables), then completed by 
some “cheese and/or yogurt”, and finally by a “dessert” 
(e.g., fruit or cake). Regarding the portion that patients 
would eat if a full French meal was served in the hospital 
or at home, 29.4 % declared that they did not eat a first 
course. Conversely, 36.5  % reported they would eat one 
portion of the second course and 23.9 % would eat half 
a portion. Most patients (58.4 %) would eat one portion 
of cheese and/or yogurt, and 56.1 % thought they would 
eat one dessert portion. Similarly, a typical French snack 
(around 11 a.m. or 4 p.m.) consists of fruit or cake with a 
tea or coffee. Over half (57.3 %) the patients declined to 
snack.
Furthermore, results showed a significant difference 
between the type of hospitalization and the consump-
tion of the first and second courses. When compared 
with inpatients, a significantly higher percentage of out-
patients declared to eat one entire portion or more of 
the first courses (33.3 vs. 20.0 %, p = 0.024) and second 
courses (47.9 vs. 24.6 %, p < 0.001).
Finally, data from open-ended question were mainly 
linked to a reduction of the usual eaten portions. A 
patient explained for example that “during five days, I 
[he] don’t eat afternoon snacks anymore… and I [he] don’t 
eat much…” while another reported that “I [he] don’t eat 
anymore during the chemotherapy” or “I must eat very 
light because all that is solid hurts my esophagus”.
#4 Food preferences
Most patients preferred salty foods (57.6 %) rather than 
sweet ones (39.6 %, p < 0.001) in general. They reported 
a preference for hot (58.7  %) rather than cold food 
(29.8  %), p  <  0.001). Concerning the textures, food cut 
into pieces was preferred by 27.8 % of patients, followed 
by creamy (20.8 %), liquid (14.1 %), minced (13.7 %) and 
lastly by blended food (9.8  %). However, sweet foods 
were as valued as salty foods when patients detailed their 
preferences. Qualitatively, the strongest message from 
patients was that the seasoning level drove their prefer-
ences, for example “I prefer foods that are spicy”, “foods 
that are peppery” or conversely “I eat strictly without 
salt” or “I like dishes that are not too much salty nor too 
much sweet”. Results about the descriptive preferences 
are then reported as percentages of responses in Table 5. 
The most enjoyed foods were fruits (49 %, including com-
potes), dairy products (45  %), and after, pasta, and red 
meat (40  %). On the other hand, more than two-thirds 
of patients (69 %) reported an aversion to specific foods, 
particularly red meat (15.4  %) and meals with sauce 
(10.9 %). The key theme identified was the preference for 
the typical French courses. It included French specialties 
(e.g., “quiche”, “bread”) and also the Mediterranean diet, 
incorporating a majority of “fruits and vegetables”, “fish” 
and “soup”.
Patients then ranked a list of the most important attrib-
utes stimulating appetite (i.e., taste, appearance, odor, 
Table 3 Treatment side effects
Type of side effects (n = 255) n (%)
Fatigue 190 (74.5)
Nausea 141 (55.3)
Dry mouth 124 (48.6)
Hypersensitivity to odors 91 (35.7)
Constipation 87 (34.1)
Diarrhea 83 (32.5)
Mouth ulcers 64 (25.1)
Swallowing difficulties 62 (24.3)
Vomiting 55 (21.6)
Persistent taste 36 (14.1)
Chewing difficulties 35 (13.7)
Others (e.g., dysgeusia) 52 (20.4)
Table 4 Side effects and oral intake impact
Type of perturbation of oral intake (n = 212) n (%)
Appetite loss 143 (66.8)
Food aversion 110 (51.4)
Satiety 85 (39.7)
Mouth pain 54 (25.2)
Abdominal pain during digestion 26 (12.1)
Others (e.g., ageusia) 23 (10.7)
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texture, quantity, packaging and other) in descending 
order of importance on a 7-point scale (1 = most impor-
tant). Taste was the most frequently cited quality to 
stimulate appetite (mean score of 2.4), followed by odor 
and appearance (both 3.0), presentation (4.1), consist-
ency (4.3) and finally quantity (4.6) (Fig. 1). Some patients 
added qualitatively that the temperature was as another 
important attribute that stimulated appetite.
Concerning snacks, less than half the patients did 
not report any taste (41.6 %) and snack type preference 
(47.5  %). However, patients indicating a taste prefer-
ence preferred sweet snacks (46.7  %) rather than salty 
ones (15.7  %, p  =  0.003) with no significant differ-
ence among biscuits (32.5 %), creamy desserts (16.5 %) 
and ice cream (20.4 %, p = 0.34). In summary, most of 
patients had reported a preference for salty meals but 
for sweet snacks. Interestingly, patients who lived in 
southern France (i.e., 56.1 % lived in Nice, Marseille or 
Montpellier) had a greater preference for ice creams 
compared with patients living in the north (26.6 vs. 
12.5  %, p  <  0.05). No other difference was found in 
responses from the diverse geographical areas. Milky 
beverages (17.6 %) were preferred less than other bever-
ages (38.0 %) such as tea, coffee or herbal tea (without 
stimulant) and fruit juices (p = 0.002). Finally, answers 
from open-ended question focused mostly on “fruits” as 
another potential snack.
#5 Nutrient‑enriched foods
Fifty-four percent of patients (n  =  129) had already 
experimented with enriched or fortified foods, 43.4 % at 
home, 36.4 % in the hospital, 19.4 % at both places. Oral 
nutritional supplements were mostly milky beverages 
(69.8 %), creamy desserts (29.5 %), and non-milky drinks 
(24.0  %). From the open-ended question, most patients 
reported to have already eaten hyperprotein soup. More 
than two-thirds of patients (70.5 %) were satisfied or very 
satisfied with the products. Among those who expressed 
dissatisfaction with the nutrient-enriched foods, the 
majority (84 %) identified taste as the major cause of their 
dissatisfaction. Qualitative data enlighten that the prod-
ucts were mostly liked because they were “easy to digest” 
while they were mostly disliked because of their “bad, 
viscous or stodgy taste”.
#6 Preferences for a new dietary product
Of the characteristics that ranked the motivation of 
purchasing a new dietary product (from 1 to 9, where 
1  =  most important), taste was considered to be the 
most important (mean score of 2.4), followed by nutri-
tional value, dietary counseling (both 3.8), and medi-
cal prescription (4.4). Patients expressed a desire to find 
these new products in supermarkets (59.6 %), community 
pharmacies (29.0  %) and dietary shops (20.4  %). Home 
delivery would also be appreciated by 17.3 % of patients. 
Preference for product form was for fresh (74.1 %), frozen 
(25.9 %) and canned products (17.3 %). The other themes 
that patients freely expressed were the visual aspect of 
Table 5 Food preferences and aversions in cancer patients
n (%)
Main preferences (n = 205)
 Fruits 100 (48.8)
 Dairy products 92 (44.9)
 Pasta 86 (42.0)
 Red meat 82 (40.0)
 Mashed potatoes 74 (36.1)
 Vegetables 74 (36.1)
 Soup 68 (33.2)
 Fish 62 (30.2)
 White meat 42 (20.5)
 Milky dessert 40 (19.5)
 Rice 26 (12.7)
 Salad 20 (9.8)
Main food aversions (n = 175)
 Red meat 27 (15.4)
 Meals and meat with sauce 19 (10.9)
 Everything 13 (7.4)
 Sweet 9 (5.1)
 Chocolate 7 (4.0)
 Cheese 7 (4.0)















Fig. 1 Percentage of patients who chose a characteristic (among 
taste, appearance, odor, consistency, quantity, packaging and other) 
as the most important sensory quality that stimulates appetite 
(n = 255)
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the product (e.g., “presentation, color, appearance”) and 
its “organic” character.
Discussion
This is one of the first studies to describe meal-related 
behaviors and food preferences of cancer patients 
within a cultural context (i.e., considering French meal 
traditions). We used patient self-reports to investigate 
descriptions and experiences of the meal situation focus-
ing on symptoms, behaviors, and changes. The majority 
of patients had a good ECOG performance status (about 
70 % were grade 0 or 1), and more than 90 % received an 
oncologic treatment. Indeed, the first remarkable result 
was that treatment-related side effects affected eating and 
drinking in 83.1 % of cases irrespective of tumor location 
and of type of treatment.
In fact, the main consequence of altered eating and 
drinking was decreased food and energy intake. In our 
study, more than 50  % of patients suffered weight loss 
≥5 %, increasing their risk of potential health complica-
tions (Dewys et  al. 1980; Andreyev et  al. 1998; Bellisle 
2003; Argilés 2005; Arends et  al. 2006; Senesse et  al. 
2014). Most patients had breast or GI tract cancer treated 
with chemotherapy. Indeed, the main treatment-induced 
side effects included fatigue, nausea, dry mouth, altered 
sensations to smell and digestive transit disorders. In 
line with previous studies (Zabernigg et  al. 2010; Coa 
et al. 2015), these side effects affected eating and drink-
ing in 83 % of patients, by inducing principally appetite 
loss and aversion to specific foods. Due to the variety of 
symptoms affecting patients, it is essential to provide a 
comprehensive approach integrating dietary advice and 
other specialists such as speech language pathologists, 
occupational therapists or social workers, depending on 
the disease and treatment (Senesse et  al. 2014). Further 
studies showed that dietary counseling reduced weight 
loss, improved quality of life, and reduced toxicity in irra-
diated patients with head and neck, and gastrointestinal 
cancer (Ravasco et al. 2005a, b; Isenring et al. 2012). Die-
tary counseling involving the prescription of a therapeu-
tically adjusted diet should be more widely provided to 
such patients. Nutritional guidelines highlight the impor-
tance of dietary counseling; however, there is a lack infor-
mation concerning the definition of dietary counseling 
used to demonstrate its benefits (Boltong et al. 2012).
Dietary counseling must include meal and food prefer-
ences within the cultural context and the patient’s home 
situation. Three out of 4 patients were concerned with 
fatigue and were not able to resume cooking and meal 
preparation immediately after treatment. Patients’ par-
ents were the main source of help even if the patient was 
as a couple. Hence, dietary counseling should also involve 
them, and more broadly the family. Then, cancer-related 
fatigue is well known to be one of the most prevalent and 
burdensome symptoms (Servaes et  al. 2002; Tomlinson 
et al. 2013) and often becomes a major distressing symp-
tom (Minton et al. 2013). The development of a specific 
physical activity intervention could reduce asthenia and 
fatigue, and may stimulate appetite thus leading to an 
increase in oral intake (Bortolon et  al. 2014). Concern-
ing meal-related behaviors and cultural context, more 
than 50 % of patients identified breakfast as their favorite 
meal. Patients also reported a preference for lunch and 
dinner at home rather than in the hospital, eating salty 
and hot meals, and food cut into pieces. In fact, our 
results highlight the importance of meals and hedonics 
food (i.e., the extent to which eating and drinking pro-
vides affect of pleasure or displeasure) for French onco-
logic patients, also documented among healthy adults in 
France (de Castro et al. 2000; Bellisle et al. 2003). In this 
study, meals (i.e., breakfast, lunch and dinner) provided 
the greatest contribution to food intake, while also dem-
onstrating a specific role for snacks. The consumption 
of snacks would appear to be a simple way to increase 
energy and protein intake. For example, almost half of all 
patients ate at least one portion of cheese and/or yogurt, 
and also one dessert portion with ice cream preference in 
the southern region of the country.
Oncologic treatment effects may differentially affect 
food preference as taste quality changes have been shown 
to be individual (Brisbois et  al. 2011). Food preference 
information compiled from six studies indicates that caf-
feinated foods and drinks, red meat and citrus fruit or 
juices are more likely to become an aversion during CT 
than other foods or beverages (Boltong and Keast 2012). 
In a recent study among hospitalised haematological can-
cer patients, fresh fruit, ice cream, cheese and mashed 
potatoes with bacon were the most desired food items 
(Okkels et al. 2016). Our results were in agreement with 
a recent qualitative study in which patients expressed a 
reduced intensity of elements of flavor (taste “fading” 
or “blending out”) (Coa et  al. 2015; Okkels et  al. 2016). 
Food hedonics are broader than the eating and drinking 
experience (Boltong and Keast 2012). They may include 
a good palatability and a psychological determination of 
the extent to which diet provides emotion of pleasure or 
displeasure. For example, in our sample, some patients 
reported enjoyment of fruit, dairy products and red 
meat, whereas these same foods repulsed others. Finally, 
qualitative data enlighten the importance of cultural hab-
its: beyond the treatment-induced side effects, patients 
reported preferences for the typical French courses, in 
particular for the “Mediterranean diet”.
Participants indicated that taste was the most important 
attribute stimulating appetite, and also the most impor-
tant benefit rewarding the purchase of a new dietary 
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product after the nutritional value itself. Also, odor and 
appearance seemed to influence appetite more than the 
quantity itself. Interestedly, a new cognitive propriety that 
may also influence appetite has emerged from the qualita-
tive data: whether the food was organic or not. First, our 
results confirmed that there are many factors that affect 
meals in cancer context, as it was shown in the natu-
ral environment (de Castro et  al. 2000). Palatability had 
only a limited influence on intake. Then, it is important 
to note that taste is often confused with flavors (Spence 
2013). Taste perception refers to those sensations that are 
elicited by the stimulation of the gustatory receptors on 
the tongue (sweet, sour, salty, bitter and more recently, 
umami—savory) (Stevenson 2009). However, people vir-
tually never experience pure isolated taste and mostly 
experience flavors, resulting from the combination of 
taste, retronasal olfaction and trigeminal inputs (Small 
2012). “Fruity”, “meaty”, “floral” and “burnt” are all flavor 
descriptions (Verhagen 2007). Actually, flavor is perhaps 
the most multimodal of all of our sensory experiences 
(Auvray and Spence 2008). Therefore, it is now timely to 
suggest that cognitive neuroscientists integrate the study 
of multisensory flavor perception in the oncology field. As 
it was demonstrated with visual–auditory stimuli in older 
adults (Laurienti et al. 2006), the use of multiple sensory 
channels may represent an effective compensatory strat-
egy to overcome the unisensory deficits induced by cancer 
treatment. There is hope that our growing psychological 
scientific understanding of multisensory flavor may help 
the food industries to deliver adjusted and more personal-
ized products for better health care.
In summary, given their impact on morbidity, mortal-
ity and quality of life (Zabernigg et al. 2010), taste and/or 
smell changes and their impact on food hedonics should 
be considered very seriously in clinical practice. Such 
data should be integrated in tools assessing quality of life 
and should be used to improve nutritional status (Hutton 
et al. 2007).
Finally, we identified essential and practical advice for 
health-care professionals in order to improve energy 
intake and to prevent significant weight loss before and 
during treatment therapy.
  • Eating and drinking are affected in most of cases dur-
ing treatment. A systematic nutritional assessment 
is required as well as a follow-up as recommended 
in guidelines (Arends et al. 2006; August et al. 2009; 
Senesse et al. 2014).
  • Focusing dietary counseling on meals, especially 
on breakfast, should be efficient to increase dietary 
intake addressed to in- and outpatients.
  • At home, dietary counseling should also involve 
patients’ parents who are the main source of help, 
and more broadly should involve the family. There-
fore, lunch and dinner could be improved easily.
  • Prescription of a therapeutic diet should be person-
alized and adjusted to the patients’ food preferences 
and meal-related behaviors, including patient’s cul-
ture (in terms of meal traditions), geographical area, 
and habits.
Additional investigations, including both qualitative 
and quantitative methods (i.e., mixed approaches), are 
necessary to further reduce the gap between self-report 
experiences and evidence-based strategies.
We have identified several limitations to our study. 
The questionnaire used to assess dietary changes may 
have been too long and complex for some patients who 
required the help of the oncology dietitian staff for its 
completion. Even if there were no biases with inter-
pretation and responses by participants who required 
some help (it concerned only a few patients), it made 
heavy the procedure for those participants. Also, it did 
not clearly ask patients about the need for counseling 
and nutritional support, nor whether participants 
presently received this service. No information was 
given about the average length of time these patients 
have been receiving treatment. Our results should be 
interpreted and generalized with caution. These con-
cerns relate specifically to the relatively low response 
rate and heterogeneity of the sample. Our study popu-
lation was purposely heterogeneous, including patients 
with different types, locations, and stages of cancer, 
and also different therapies. While published studies 
usually focus on a precise disease and treatment, we 
aimed to reflect the diversity of patients met in real 
practice.
In conclusion, this study showed a high prevalence of 
symptoms reducing appetite and changes to meal and 
food preference during oncologic treatment. Individual 
dietary counseling has been shown to reduce morbidity 
and mortality, and to improve functional performance 
and well-being (Bauer 2007; Meuric and Besnard 2012). 
However international guidelines addressing dietary 
counseling should incorporate meal and food preferences 
in the cultural context specific to each country (i.e. meal 
traditions).
Abbreviations
GI: gastro‑intestinal; CT: chemotherapy; ECOG: Eastern Cooperative Oncology 
Group; ICM: Cancer Institute of Montpellier; ingesta‑VAS: ingesta visual/verbal 
analogue scale.
Authors’ information
The pilot EGN has been working as a psychologist and a neuropsychologist 
for more than 12 years in geriatrics, neurology and more recently in oncology. 
Her researches aim to understand the psychological, cognitive and dynamic 
processes involved in health‑related quality of life and well‑being. She wrote 
Page 9 of 10Guerdoux‑Ninot et al. SpringerPlus  (2016) 5:810 
the manuscript and gave a human and social light in the data interpretation. 
Her contribution matched with the PS’s points of view (the coordinator of 
Supportive Care and Head of Clinical Nutrition and Gastroenterology in the 
Cancer Institute of Montpellier) who conceived the study, and also completed 
the other authors’ contribution of this study.
Author details
1 SIRIC Montpellier Cancer, Cancer Institute of Montpellier (ICM)‑Val d’Aurelle, 
208 avenue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 
5, France. 2 Epsylon Research Unit EA 4556 Laboratory, Departments of Sport 
Sciences, Medicine and Psychology, University of Montpellier and University 
Paul Valery, Rue du Pr. Henri Serre, 34000 Montpellier, France. 3 Depart‑
ment of Exercise Science, The Richard J. Renaud Science Complex, Room 
SP‑165‑17, Concordia University, Loyola Campus, 7141 Sherbrooke Street West, 
Montreal, QC H4B 1R6, Canada. 4 McGill Nutrition and Performance Labora‑
tory (MNUPAL), McGill University Health Centre, Suite 105B, Place Vendome, 
5252 de Maisonneuve Ouest, Montreal, QC H4A 3S5, Canada. 5 Department 
of Clinical Nutrition and Gastroenterology, Cancer Institute of Montpel‑
lier (ICM), Val d’Aurelle, 208 avenue des Apothicaires, Parc Euromédecine, 
34298 Montpellier Cedex 5, France. 6 Department of Clinical Research, Cancer 
Institute of Montpellier (ICM), Val d’Aurelle, 208 avenue des Apothicaires, Parc 
Euromédecine, 34298 Montpellier Cedex 5, France. 7 Biostatistics Unit, Cancer 
Institute of Montpellier (ICM), Val d’Aurelle, 208 avenue des Apothicaires, Parc 
Euromédecine, 34298 Montpellier Cedex 5, France. 8 Department of Dietetic 
and Nutrition, Curie Institute of Paris, 26 rue d’Ulm, 75248 Paris Cedex 05, 
France. 9 Department of Dietetic, Centre Francois Baclesse of Caen, 3 avenue 
du Général Harris, BP5026, 14076 Caen, France. 10 Department of Dietetic, 
Centre Antoine Lacassagne of Nice, 33 Avenue de Valombrose, 06189 Nice 
Cedex 2, France. 11 Group of Nutrition and Dietary Committees of Anti‑Cancer 
Centers (Interclan CLCC), Villejuif, France. 12 Agricultural, Food and Nutritional 
Science, University of Alberta, Edmonton, AB T6G 2P5, Canada. 
Authors’ contributions
EGN was involved in data analysis, data interpretation and manuscript writ‑
ing, RDK was involved in drafting the manuscript and revising it critically, CJ 
was involved in data collection at the Cancer Institute of Montpellier and 
manuscript preparation, MJ was involved in data analysis and manuscript 
preparation, JM was involved in data collection at the Curie Institute of Paris, 
BP was involved in data collection at Centre Francois Baclesse of Caen, SB was 
involved in data collection at the Centre Antoine Lacassagne of Nice, GN was 
involved in revising the manuscript critically, JC was involved in manuscript 
draft, WW was involved in data interpretation, in particular the intercultural 
angles, and manuscript preparation, ST was involved in data analysis and 
manuscript preparation, and PS was involved in conceiving the study, study 
design, data interpretation and manuscript preparation. All authors read and 
approved the final manuscript.
Acknowledgements
This study was supported by the SIRIC Montpellier Cancer (Grant INCa‑DGOS‑
Inserm 6045) which was not involved in study design; in the collection, 
analysis and interpretation of data; in the writing of the report; and in the deci‑
sion to submit the article for publication. All authors critically reviewed the 
manuscript and approved the version for submission. The authors are grateful 
to the Curie Institute of Paris, the Centre Antoine Lacassagne of Nice, the 
Centre Francois Baclesse of Caen, and the Paoli Calmettes Institute of Marseille, 
in particular Françoise Ducès, for taking part in the study and for supplying 
the completed questionnaires. They would like to thank Eliane Courties for 
advice and expertise in the dietary industry, and Pauline Monier for assistance 
in filling in the questionnaires. They also thank Pr. Marc Ychou and Dr. Vanessa 
Guillaumon for their support. They are grateful to the dietetic staff for their 
assistance with patient recruitment toward the end of the study and their 
support in completing the study.
Competing interests
The authors declare that they have no competing interests.
Received: 21 January 2016   Accepted: 8 June 2016
References
Andreyev HJN, Norman AR, Oates J, Cunningham D (1998) Why do patients 
with weight loss have a worse outcome when undergoing chemo‑
therapy for gastrointestinal malignancies? Eur J Cancer 34:503–509. 
doi:10.1016/S0959‑8049(97)10090‑9
Arends J, Bodoky G, Bozzetti F et al (2006) ESPEN guidelines on enteral 
nutrition: non‑surgical oncology. Clin Nutr Edinb Scotl 25:245–259. 
doi:10.1016/j.clnu.2006.01.020
Argilés JM (2005) Cancer‑associated malnutrition. Eur J Oncol Nurs 9:S39–S50. 
doi:10.1016/j.ejon.2005.09.006
August DA, Huhmann MB, American Society for Parenteral and Enteral 
Nutrition (A.S.P.E.N.) Board of Directors (2009) A.S.P.E.N. clinical guide‑
lines: nutrition support therapy during adult anticancer treatment 
and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 
33:472–500. doi:10.1177/0148607109341804
Auvray M, Spence C (2008) The multisensory perception of flavor. Conscious 
Cogn 17:1016–1031. doi:10.1016/j.concog.2007.06.005
Bauer J (2007) Nutritional management and dietary guidelines for cancer 
cachexia. Eur Oncol Haematol 00:12. doi:10.17925/EOH.2007.0.2.12
Bellisle F (2003) Contribution of snacks and meals in the diet of French 
adults: a diet‑diary study. Physiol Amp Behav 79:183–189. doi:10.1016/
S0031‑9384(03)00088‑X
Bellisle F, Dalix AM, Mennen L et al (2003) Contribution of snacks and meals in 
the diet of French adults: a diet‑diary study. Physiol Behav 79:183–189. 
doi:10.1016/S0031‑9384(03)00088‑X
Boltong A, Keast R (2012) The influence of chemotherapy on taste perception 
and food hedonics: a systematic review. Cancer Treat Rev 38:152–163. 
doi:10.1016/j.ctrv.2011.04.008
Boltong A, Keast R, Aranda S (2012) Experiences and consequences of altered 
taste, flavour and food hedonics during chemotherapy treatment. Sup‑
port Care Cancer 20:2765–2774. doi:10.1007/s00520‑012‑1398‑7
Bortolon C, Krikorian A, Carayol M et al (2014) Cancer‑related fatigue in breast 
cancer patients after surgery: a multicomponent model using partial 
least squares‑path modeling: a multicomponent model of fatigue in 
breast cancer. Psychooncology 23:444–451. doi:10.1002/pon.3438
Brisbois TD, de Kock IH, Watanabe SM et al (2011) Characterization of chem‑
osensory alterations in advanced cancer reveals specific chemosensory 
phenotypes impacting dietary intake and quality of life. J Pain Symptom 
Manag 41:673–683. doi:10.1016/j.jpainsymman.2010.06.022
Coa KI, Epstein JB, Ettinger D et al (2015) The impact of cancer treatment on 
the diets and food preferences of patients receiving outpatient treat‑
ment. Nutr Cancer 67:339–353. doi:10.1080/01635581.2015.990577
de Castro J (2000) Palatability and intake relationships in free‑living humans 
characterization and independence of influence in North Americans. 
Physiol Behav 70:343–350. doi:10.1016/S0031‑9384(00)00264‑X
de Castro JM, Bellisle F, Dalix AM (2000) Palatability and intake relationships 
in free‑living humans: measurement and characterization in the French. 
Physiol Behav 68:271–277. doi:10.1016/S0031‑9384(99)00166‑3
Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior 
to chemotherapy in cancer patients. Eastern Cooperative Oncology 
Group. Am J Med 69:491–497
Epstein JB, Barasch A (2010) Taste disorders in cancer patients: pathogenesis, 
and approach to assessment and management. Oral Oncol 46:77–81. 
doi:10.1016/j.oraloncology.2009.11.008
Epstein JB, Phillips N, Parry J et al (2002) Quality of life, taste, olfactory and oral 
function following high‑dose chemotherapy and allogeneic hematopoi‑
etic cell transplantation. Bone Marrow Transpl 30:785–792. doi:10.1038/
sj.bmt.1703716
Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of 
cancer cachexia: an international consensus. Lancet Oncol 12:489–495. 
doi:10.1016/S1470‑2045(10)70218‑7
Gamper E‑M, Zabernigg A, Wintner LM et al (2012) Coming to your senses: 
detecting taste and smell alterations in chemotherapy patients. A 
systematic review. J Pain Symptom Manag 44:880–895. doi:10.1016/j.
jpainsymman.2011.11.011
Hovan AJ, Williams PM, Stevenson‑Moore P et al (2010) A systematic review of 
dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–
1087. doi:10.1007/s00520‑010‑0902‑1
Page 10 of 10Guerdoux‑Ninot et al. SpringerPlus  (2016) 5:810 
Hutton JL, Baracos VE, Wismer WV (2007) Chemosensory dysfunction is 
a primary factor in the evolution of declining nutritional status and 
quality of life in patients with advanced cancer. J Pain Symptom Manag 
33:156–165. doi:10.1016/j.jpainsymman.2006.07.017
Irune E, Dwivedi RC, Nutting CM, Harrington KJ (2014) Treatment‑related dys‑
geusia in head and neck cancer patients. Cancer Treat Rev 40:1106–1117. 
doi:10.1016/j.ctrv.2014.06.011
Isenring EA, Bauer JD, Capra S (2007) Nutrition support using the American 
Dietetic Association medical nutrition therapy protocol for radiation 
oncology patients improves dietary intake compared with standard prac‑
tice. J Am Diet Assoc 107:404–412. doi:10.1016/j.jada.2006.12.007
Isenring E, Capra S, Bauer J (2012) Nutrition support, quality of life and 
clinical outcomes. J Hum Nutr Diet 25:505–506; author reply 507–508. 
doi:10.1111/j.1365‑277X.2011.01221.x
Kong H, Kwon OK, Yu W (2012) Changes of quality of life after gastric cancer 
surgery. J Gastric Cancer 12:194–200. doi:10.5230/jgc.2012.12.3.194
Laurienti PJ, Burdette JH, Maldjian JA, Wallace MT (2006) Enhanced multi‑
sensory integration in older adults. Neurobiol Aging 27:1155–1163. 
doi:10.1016/j.neurobiolaging.2005.05.024
McQuestion M, Fitch M, Howell D (2011) The changed meaning of food: physi‑
cal, social and emotional loss for patients having received radiation treat‑
ment for head and neck cancer. Eur J Oncol Nurs Off J Eur Oncol Nurs Soc 
15:145–151. doi:10.1016/j.ejon.2010.07.006
Meuric J, Besnard I (2012) Nutrition chez le patient adulte atteint de cancer: 
quand doit‑on proposer un conseil diététique personnalisé? Nutr Clin 
Métab 26:197–218. doi:10.1016/j.nupar.2012.10.006
Minton O, Berger A, Barsevick A et al (2013) Cancer‑related fatigue and its 
impact on functioning: cancer‑related fatigue. Cancer 119:2124–2130. 
doi:10.1002/cncr.28058
Okkels SL, Bredie WLP, Klausen TW, Beck AM (2016) An investigation into 
between‑meal food desires among hospitalised haematological cancer 
patients. Clin Nutr Edinb Scotl 35:440–445. doi:10.1016/j.clnu.2015.03.010
Ravasco P, Monteiro‑Grillo I, Marques Vidal P, Camilo ME (2005a) Impact of 
nutrition on outcome: a prospective randomized controlled trial in 
patients with head and neck cancer undergoing radiotherapy. Head Neck 
27:659–668. doi:10.1002/hed.20221
Ravasco P, Monteiro‑Grillo I, Vidal PM, Camilo ME (2005b) Dietary counseling 
improves patient outcomes: a prospective, randomized, controlled trial 
in colorectal cancer patients undergoing radiotherapy. J Clin Oncol Off J 
Am Soc Clin Oncol 23:1431–1438. doi:10.1200/JCO.2005.02.054
Ruo Redda MG, Allis S (2006) Radiotherapy‑induced taste impairment. Cancer 
Treat Rev 32:541–547. doi:10.1016/j.ctrv.2006.06.003
Sandelowski M (2010) What’s in a name? Qualitative description revisited. Res 
Nurs Health 33:77–84
Senesse P, Bachmann P, Bensadoun R‑J et al (2014) Clinical nutrition guidelines 
of the French Speaking Society of Clinical Nutrition and Metabolism 
(SFNEP): summary of recommendations for adults undergoing non‑
surgical anticancer treatment. Dig Liver Dis 46:667–674. doi:10.1016/j.
dld.2014.01.160
Servaes P, Verhagen S, Bleijenberg G (2002) Determinants of chronic fatigue 
in disease‑free breast cancer patients: a cross‑sectional study. Ann Oncol 
13:589–598
Small DM (2012) Flavor is in the brain. Physiol Behav 107:540–552. 
doi:10.1016/j.physbeh.2012.04.011
Spence C (2013) Multisensory flavour perception. Curr Biol 23:R365–R369. 
doi:10.1016/j.cub.2013.01.028
Stevenson R (2009) The psychology of flavour. Oxford University Press, Oxford
Thibault R, Chikhi M, Clerc A et al (2011) Assessment of food intake in hospi‑
talised patients: a 10‑year comparative study of a prospective hospital 
survey. Clin Nutr 30:289–296. doi:10.1016/j.clnu.2010.10.002
Tomlinson D, Hinds PS, Ethier M‑C et al (2013) Psychometric properties 
of instruments used to measure fatigue in children and adolescents 
with cancer: a systematic review. J Pain Symptom Manage 45:83–91. 
doi:10.1016/j.jpainsymman.2012.02.010
Verhagen JV (2007) The neurocognitive bases of human multimodal food 
perception: consciousness. Brain Res Rev 53:271–286. doi:10.1016/j.
brainresrev.2006.09.002
Zabernigg A, Gamper E‑M, Giesinger JM et al (2010) Taste alterations in cancer 
patients receiving chemotherapy: a neglected side effect? Oncologist 
15:913–920. doi:10.1634/theoncologist.2009‑0333
